Scott Canute - Flexion Therapeutics Director
Director
Mr. Scott A. Canute serves as Independent Director of Flexion Therapeutics, Inc. Mr. Canute has served as one of our directors since 2015. Mr. Canute served as President of Global Manufacturing and Corporationrationrate Operations at Genzyme Corporation from 2010 to 2011. Prior to joining Genzyme, Mr. Canute spent 25 years at Eli Lilly and Company and served as President, Global Manufacturing Operations from 2004 to 2007. Mr. Canute currently serves as Executive Director of Immunomedics, Inc., a biopharmaceutical company focused on antibody drug conjugates, and he serves on the board of directors of Proteon Therapeutics, a biopharmaceutical company focused on renal and vascular disease and Akebia Therapeutics, Inc., a publicly traded biopharmaceutical company focused on renal disease. Mr. Canute previously served as a member of the board of directors of AlloCure, Inc., Inspiration Biopharmaceuticals, Inc., Oncobiologics, Inc., the National Association of Manufacturers and the Indiana Manufacturers Association since 2015.
| Age | 57 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Phone | 781 305-7777 |
| Web | www.flexiontherapeutics.com |
Flexion Therapeutics Management Efficiency
The company has return on total asset (ROA) of (18.99) % which means that it has lost $18.99 on every $100 spent on assets. This is way below average. Flexion Therapeutics' management efficiency ratios could be used to measure how well Flexion Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 228.9 M in liabilities. Flexion Therapeutics has a current ratio of 4.52, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Flexion Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Flexion Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Flexion Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Flexion to invest in growth at high rates of return. When we think about Flexion Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Robert Herz | Morgan Stanley | 67 | |
| Nobuyuki Hirano | Morgan Stanley | 69 | |
| Hutham Olayan | Morgan Stanley | 65 | |
| Jami Miscik | Morgan Stanley | 56 | |
| Robert Schriesheim | Skyworks Solutions | 57 | |
| Patrick Willcutts | Morgan Stanley | N/A | |
| Alistair Darling | Morgan Stanley | 66 | |
| Richard Lieb | SEI Investments | 66 | |
| Christine King | Skyworks Solutions | 68 | |
| James Owens | Morgan Stanley | 71 | |
| Kimberly Stevenson | Skyworks Solutions | 55 | |
| Elizabeth Corley | Morgan Stanley | 64 | |
| Timothy Furey | Skyworks Solutions | 59 | |
| Erskine Bowles | Morgan Stanley | 70 | |
| Carmen Romeo | SEI Investments | 73 | |
| Kevin Beebe | Skyworks Solutions | 59 | |
| Alexander Whitelam | SEI Investments | N/A | |
| Perry Traquina | Morgan Stanley | 63 | |
| Sarah Blumenstein | SEI Investments | 70 | |
| Thomas Glocer | Morgan Stanley | 61 | |
| Mary Schapiro | Morgan Stanley | 65 | |
Management Performance
| Return On Asset | -18.99 |
Flexion Therapeutics Leadership Team
Elected by the shareholders, the Flexion Therapeutics' board of directors comprises two types of representatives: Flexion Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Flexion. The board's role is to monitor Flexion Therapeutics' management team and ensure that shareholders' interests are well served. Flexion Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Flexion Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Arkowitz, CFO, Principal Financial Officer and Principal Accounting Officer | ||
| Sandesh Mahatme, Director | ||
| Scott Canute, Director | ||
| Mark Levine, Senior Vice President General Counsel, Secretary | ||
| Kerry Wentworth, Chief Regulatory Officer | ||
| Dan Thornton, Vice President - Market Access | ||
| John Magee, Vice President - Sales | ||
| Neil Bodick, Chief Medical Officer & Co-Founder | ||
| Mark Fraga, Vice President - Marketing | ||
| Michael Clayman, CEO, Co-Founder, Board Member | ||
| Ann Merrifield, Director | ||
| Alan Milinazzo, Independent Director | ||
| Jon Mahlowitz, VP of Legal Affairs | ||
| Frederick Driscoll, CFO and Principal Accounting Officer | ||
| Heath Lukatch, Independent Director | ||
| Christina Willwerth, Chief Strategy Officer | ||
| Patrick Mahaffy, Chairman of the Board | ||
| Samuel Colella, Independent Director | ||
| Yamo Deniz, Chief Medical Officer | ||
| Mark Stejbach, Director | ||
| Scott Kelley, Vice President - Medical Affairs |
Flexion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Flexion Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -18.99 | |||
| Profit Margin | (92.52) % | |||
| Operating Margin | (71.24) % | |||
| Current Valuation | 408.79 M | |||
| Shares Outstanding | 49.94 M | |||
| Shares Owned By Insiders | 3.58 % | |||
| Shares Owned By Institutions | 92.20 % | |||
| Number Of Shares Shorted | 5.67 M | |||
| Price To Earning | (8.29) X | |||
| Price To Book | 35.88 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Flexion Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Flexion Therapeutics' short interest history, or implied volatility extrapolated from Flexion Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Flexion Stock
If you are still planning to invest in Flexion Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Flexion Therapeutics' history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |